EXELIXIS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.9 USD | -1.76% |
|
-5.71% | -12.94% |
| 01:59pm | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
| 05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | -1.81% | -5.71% | -12.94% | +7.10% | +9.17% | 6.2B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
